Pullback in pharma has created a compelling buying opportunity
The fundamentals are good for the health care sector in general. Recent news articles on drug pricing/gouging are not likely to effect meaningful change for the overall group dynamics in my opinion…
VRX, Valeant Pharmaceuticals remains a mystery. What does the CFO see?
Overall Score:
Trading Chart: 0
